

Christian Brander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2657221/publications.pdf>

Version: 2024-02-01

96
papers

7,983
citations

76294

40
h-index

49868

87
g-index

98
all docs

98
docs citations

98
times ranked

8241
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope. <i>Vaccines</i> , 2022, 10, 484.	2.1	2
2	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. <i>EBioMedicine</i> , 2022, 78, 103956.	2.7	5
3	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
4	Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T-Cell antiviral responses. <i>Cell Reports</i> , 2021, 35, 109103.	2.9	4
5	Considerations for successful therapeutic immunization in HIV cure. <i>Current Opinion in HIV and AIDS</i> , 2021, Publish Ahead of Print, 257-261.	1.5	5
6	Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1032-1040.	1.3	2
7	Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice. <i>Vaccines</i> , 2020, 8, 678.	2.1	4
8	TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses. <i>Journal of Immunology</i> , 2020, 205, 3348-3357.	0.4	3
9	SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development. <i>Vaccines</i> , 2020, 8, 444.	2.1	11
10	In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. <i>PLoS Pathogens</i> , 2020, 16, e1008607.	2.1	13
11	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 418-428.	1.8	10
12	In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. <i>Frontiers in Immunology</i> , 2020, 11, 418.	2.2	23
13	A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9981-9990.	3.3	51
14	HIVconsV Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). <i>Frontiers in Immunology</i> , 2020, 11, 823.	2.2	55
15	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?. <i>Frontiers in Immunology</i> , 2020, 11, 573928.	2.2	9
16	Novel Approaches Towards a Functional Cure of HIV/AIDS. <i>Drugs</i> , 2020, 80, 859-868.	4.9	26
17	Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. <i>Vaccines</i> , 2019, 7, 78.	2.1	16
18	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EClinicalMedicine</i> , 2019, 11, 65-80.	3.2	52

#	ARTICLE	IF	CITATIONS
19	Strong sex bias in elite control of paediatric HIV infection. <i>Aids</i> , 2019, 33, 67-75.	1.0	22
20	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. <i>Trials</i> , 2019, 20, 361.	0.7	31
21	Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. <i>PLoS ONE</i> , 2019, 14, e0212347.	1.1	4
22	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. <i>Vaccines</i> , 2019, 7, 209.	2.1	25
23	Zip6 Transporter Is an Essential Component of the Lymphocyte Activation Machinery. <i>Journal of Immunology</i> , 2019, 202, 441-450.	0.4	21
24	Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
25	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. <i>PLoS ONE</i> , 2018, 13, e0208345.	1.1	8
26	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. <i>Aids</i> , 2018, 32, 2533-2545.	1.0	65
27	Benzyl-2-Acetamido-2-Deoxy- β -D-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro. <i>Frontiers in Immunology</i> , 2018, 8, 2010.	2.2	5
28	HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency. <i>Frontiers in Microbiology</i> , 2018, 9, 1066.	1.5	13
29	HIV T-Cell Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 31-51.	0.8	16
30	A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. <i>Microbes and Infection</i> , 2017, 19, 69-74.	1.0	9
31	Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). <i>Aids</i> , 2017, 31, 321-332.	1.0	38
32	Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. <i>PLoS ONE</i> , 2017, 12, e0176418.	1.1	27
33	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. <i>PLoS ONE</i> , 2017, 12, e0184929.	1.1	13
34	Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Na ⁺ ve HIV-Infected Individuals. <i>PLoS ONE</i> , 2016, 11, e0147571.	1.1	3
35	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. <i>Aids</i> , 2016, 30, 553-562.	1.0	6
36	Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection. <i>Retrovirology</i> , 2015, 12, 80.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. <i>Aids</i> , 2015, 29, 1309-1318.	1.0	10
38	FARMS: A New Algorithm for Variable Selection. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	2
39	Comprehensive serological profiling of human populations using a synthetic human virome. <i>Science</i> , 2015, 348, aaa0698.	6.0	364
40	Immune Screening Identifies Novel T Cell Targets Encoded by Antisense Reading Frames of HIV-1. <i>Journal of Virology</i> , 2015, 89, 4015-4019.	1.5	24
41	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. <i>Journal of Translational Medicine</i> , 2015, 13, 60.	1.8	84
42	Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses. <i>PLoS Pathogens</i> , 2015, 11, e1004658.	2.1	42
43	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	1.3	56
44	T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. <i>Cytotherapy</i> , 2015, 17, 1280-1291.	0.3	11
45	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. <i>Journal of Infectious Diseases</i> , 2015, 211, 936-946.	1.9	18
46	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. <i>PLoS ONE</i> , 2015, 10, e0141456.	1.1	24
47	Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques. <i>PLoS ONE</i> , 2014, 9, e86254.	1.1	47
48	Direct Interrogation of Viral Peptides Presented by the Class I HLA of HIV-Infected T Cells. <i>Journal of Virology</i> , 2014, 88, 12992-13004.	1.5	64
49	Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A194-A194.	0.5	0
50	Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells. <i>Journal of Immunology</i> , 2014, 193, 1988-1997.	0.4	118
51	Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3057-3060.	1.3	26
52	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e87334.	1.1	15
53	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. <i>Journal of Translational Medicine</i> , 2013, 11, 48.	1.8	3
54	HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32. <i>Immunobiology</i> , 2013, 218, 543-547.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients. <i>European Journal of Immunology</i> , 2013, 43, 1545-1554.	1.6	1
56	HIV-1 p24 _{gag} Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice. <i>PLoS ONE</i> , 2013, 8, e60245.	1.1	44
57	Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. <i>PLoS Pathogens</i> , 2012, 8, e1002529.	2.1	306
58	Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. <i>Journal of Virology</i> , 2012, 86, 12643-12654.	1.5	49
59	CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control. <i>PLoS ONE</i> , 2012, 7, e29717.	1.1	117
60	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011, 9, 208.	1.8	143
61	High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control. <i>Journal of Virology</i> , 2011, 85, 9334-9345.	1.5	120
62	Increased Breadth and Depth of Cytotoxic T Lymphocytes Responses against HIV-1-B Nef by Inclusion of Epitope Variant Sequences. <i>PLoS ONE</i> , 2011, 6, e17969.	1.1	20
63	Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. <i>Journal of Experimental Medicine</i> , 2010, 207, 61-75.	4.2	52
64	Virological, Immune and Host genetics Markers in the Control of HIV Infection. <i>Disease Markers</i> , 2009, 27, 105-120.	0.6	45
65	HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins. <i>PLoS ONE</i> , 2009, 4, e6687.	1.1	148
66	Virological, immune and host genetics markers in the control of HIV infection. <i>Disease Markers</i> , 2009, 27, 105-20.	0.6	28
67	HLA class I supertypes: a revised and updated classification. <i>BMC Immunology</i> , 2008, 9, 1.	0.9	591
68	Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance. <i>Journal of Virology</i> , 2008, 82, 3147-3153.	1.5	55
69	Structural and Functional Constraints Limit Options for Cytotoxic T-Lymphocyte Escape in the Immunodominant HLA-B27-Restricted Epitope in Human Immunodeficiency Virus Type 1 Capsid. <i>Journal of Virology</i> , 2008, 82, 5594-5605.	1.5	138
70	Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. <i>Aids</i> , 2008, 22, 447-456.	1.0	29
71	Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads. <i>PLoS ONE</i> , 2008, 3, e1424.	1.1	146
72	Lytic and Latent Antigens of the Human Gammaherpesviruses Kaposi's Sarcoma-Associated Herpesvirus and Epstein-Barr Virus Induce T-Cell Responses with Similar Functional Properties and Memory Phenotypes. <i>Journal of Virology</i> , 2007, 81, 4904-4908.	1.5	32

#	ARTICLE	IF	CITATIONS
73	Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication. <i>Journal of Virology</i> , 2007, 81, 12382-12393.	1.5	299
74	Increased Sequence Diversity Coverage Improves Detection of HIV-Specific T Cell Responses. <i>Journal of Immunology</i> , 2007, 179, 6638-6650.	0.4	32
75	Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 183-188.	1.5	4
76	Extensive HLA class I allele promiscuity among viral CTL epitopes. <i>European Journal of Immunology</i> , 2007, 37, 2419-2433.	1.6	120
77	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. <i>Nature Medicine</i> , 2007, 13, 46-53.	15.2	910
78	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. <i>Nature Immunology</i> , 2006, 7, 173-178.	7.0	209
79	The challenges of host and viral diversity in HIV vaccine design. <i>Current Opinion in Immunology</i> , 2006, 18, 430-437.	2.4	43
80	Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control. <i>Journal of Virology</i> , 2006, 80, 3122-3125.	1.5	275
81	Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses. <i>Journal of Immunology</i> , 2006, 176, 4094-4101.	0.4	150
82	Î±EÎ²7 (CD103) Expression Identifies a Highly Active, Tonsil-Resident Effector-Memory CTL Population. <i>Journal of Immunology</i> , 2005, 175, 4355-4362.	0.4	54
83	Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". <i>Journal of Translational Medicine</i> , 2005, 3, 20.	1.8	34
84	Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides. <i>Journal of Virology</i> , 2004, 78, 4463-4477.	1.5	171
85	IL-8 responsiveness defines a subset of CD8 T cells poised to kill. <i>Blood</i> , 2004, 104, 3463-3471.	0.6	89
86	Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. <i>Journal of Immunological Methods</i> , 2003, 275, 19-29.	0.6	129
87	Gradual adaptation of HIV to human host populations: good or bad news?. <i>Nature Medicine</i> , 2003, 9, 1359-1362.	15.2	61
88	Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. <i>Blood</i> , 2002, 100, 698-700.	0.6	31
89	Evolution and transmission of stable CTL escape mutations in HIV infection. <i>Nature</i> , 2001, 412, 334-338.	13.7	523
90	Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection. <i>Journal of Experimental Medicine</i> , 2001, 193, 169-180.	4.2	363

#	ARTICLE	IF	CITATIONS
91	Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27-Restricted Cytotoxic T Lymphocyte Responses. <i>Journal of Experimental Medicine</i> , 2001, 193, 375-386.	4.2	424
92	Substantial Differences in Specificity of HIV-Specific Cytotoxic T Cells in Acute and Chronic HIV Infection. <i>Journal of Experimental Medicine</i> , 2001, 193, 181-194.	4.2	249
93	Efficient generation of human T cells from a tissue-engineered thymic organoid. <i>Nature Biotechnology</i> , 2000, 18, 729-734.	9.4	156
94	Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide. <i>European Journal of Immunology</i> , 1993, 23, 3217-3223.	1.6	23
95	Discrimination of human CD4 T cell clones based on their reactivity with antigen-presenting T cells. <i>European Journal of Immunology</i> , 1992, 22, 2295-2302.	1.6	25
96	T-Follicular-Like CD8+ T Cell Responses in Chronic HIV Infection Are Associated With Virus Control and Antibody Isotype Switching to IgG. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1